Carcinoid Syndrome Diarrhea Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The carcinoid syndrome diarrhea treatment market size is expected to increase from USD 609 million in 2025 to USD 638.36 million in 2026 and reach USD 851.66 million by 2031, growing at a CAGR of 5.94% over 2026-2031. This report is segmented by Treatment Modality (SSA, Telotristat Ethyl, Supportive, Interventional), Drug Class (Somatostatin Analogs, Telotristat Ethyl, Radiopharmaceuticals, Supportive), End User (Hospitals, Clinics, Cancer Centers, Homecare), Disease Setting (Newly Diagnosed, SSA-Controlled, Refractory, Advanced), Geography (North America, Europe, APAC, MEA, South America)

Global Carcinoid Syndrome Diarrhea Treatment Market Trends and Insights

Rising Diagnosis and Prevalence of Neuroendocrine Tumors

NET incidence is increasing through factors beyond improved screening alone. Grade 1 tumor prevalence in the United States increased from 0.00023% in 2001 to 0.02993% in 2021. Ontario recorded a 6.5-fold increase in GEP-NEN incidence from 2000 to 2023, and the increase was concentrated in nonmetastatic presentations. Five-year overall survival across NETs reached 77.4% in the SEER-22 cohort, lengthening the time during which patients may need symptom management. Localized disease incidence also increased from 2.1 to 4.3 per 100,000 between 2004 and 2021. These patterns create a larger future pool that may progress to metastatic disease and carcinoid syndrome, supporting the carcinoid syndrome diarrhea treatment market over a longer period.

Recurring Use of Long-Acting Somatostatin Analogs

Long-acting somatostatin analogs generate recurring revenue because treatment can continue for an indefinite period. The 2025 ASCO guideline places somatostatin analogs in first-line care for functional carcinoid syndrome. The guideline also supports shorter intervals from 28 to 21 days or doses of 40 mg to 60 mg when symptoms break through. This can raise treatment use beyond a standard labeled monthly schedule. Specialist NET centers and multidisciplinary care help formalize these treatment decisions, especially in established referral systems. The carcinoid syndrome diarrhea industry continues to rely on this recurring treatment pattern even as generic products change the economics of the category.

High Cost of Long-Term and Radioligand Therapies

Long-term treatment costs can restrict use even when clinical value is well established. Branded long-acting SSA therapy costs more than USD 10,000 annually per U.S. patient, while a PRRT course with 177Lu-DOTATATE can exceed USD 120,000 in major markets. A 2025 cost-effectiveness analysiscalculated an incremental cost-effectiveness ratio of USD 66,761 per quality-adjusted life year for first-line PRRT versus octreotide LAR. Generic SSA products may lower first-line medication costs in the United States, but they also reduce the pool of branded revenue available for innovation. Reimbursement variation and direct patient costs can limit uptake in middle-income countries. These pressures constrain the carcinoid syndrome diarrhea treatment market most sharply where insurance coverage and public reimbursement are less developed.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Treatment Options for Refractory Diarrhea
• Rising Demand for Patient-Friendly Oral and Home-Based Treatment
• Limited Access to NET Specialists, PRRT, and Nuclear-Medicine Infrastructure

Segment Analysis

Somatostatin analog therapy accounted for 56.4% of the carcinoid syndrome diarrhea treatment market size by treatment modality in 2025. Its position reflects long clinical use, multiple guideline endorsements, and relevance across newly diagnosed and SSA-controlled disease. Long-acting octreotide LAR and lanreotide autogel support continuing treatment through regular administration. Dose escalation can extend use beyond the standard monthly schedule when symptoms recur. The products remain a practical backbone of the carcinoid syndrome diarrhea industry because they address hormone secretion and symptom control.

Serotonin synthesis inhibitor therapy is projected to expand at an 11.8% CAGR through 2031, making it the fastest-growing modality. This segment is supported by the recognition of refractory carcinoid syndrome diarrhea as a distinct clinical setting. Telotristat ethyl is used as an add-on treatment for patients who are not adequately controlled on SSA therapy. The ASCO guideline provides a clearer basis for its use in this setting. Supportive products such as loperamide, diphenoxylate, pancreatic enzymes, and bile-acid sequestrants remain important, particularly where SSA access is limited or patients have SSA-related pancreatic exocrine insufficiency. Advanced and interventional treatments, including PRRT, liver-directed therapy, and surgery, serve patients with more complex disease.

Octreotide held 28.2% of the carcinoid syndrome diarrhea treatment market share by drug type in 2025. It remains a widely prescribed first-line therapy because clinicians have extensive experience with its use. Its long-acting depot formulation supports symptom control and reduces hormone secretion. Guideline support and physician familiarity continue to underpin use across major healthcare systems. Teva launchedthe first U.S. generic octreotide acetate for injectable suspension in October 2024, and the product was indicated for severe diarrhea and flushing associated with metastatic carcinoid tumors.

Telotristat ethyl is forecast to grow at a 12.2% CAGR through 2031. Its mechanism targets peripheral serotonin production, which distinguishes it from SSA therapy. It is increasingly used alongside somatostatin analogs when diarrhea persists despite base treatment. Clinical evidence and guideline endorsement support its commercial outlook. The drug class structure of the carcinoid syndrome diarrhea industry therefore separates an established SSA base from a faster-growing serotonin-targeted option. Radiopharmaceuticals and supportive therapies complete the treatment set, but each has a different access profile and role in the care pathway.

Complete Report Scope:

• By Treatment Modality
  • Somatostatin Analog Therapy (SSA)
  • Serotonin Synthesis Inhibitor Therapy
  • Targeted & Radioligand Therapy
  • Supportive and Symptom Management Therapy
• By Drug Type
  • Octreotide
  • Lanreotide
  • Pasireotide
  • Telotristat Ethyl
  • Lutetium Lu 177 Dotatate
  • Others
• By End User
  • Hospitals
  • Specialty Clinics
  • Cancer Institutions & Treatment Centers
  • Homecare Settings
• By Disease
  • Newly Diagnosed Carcinoid Syndrome
  • SSA-Controlled Diarrhea
  • Refractory Diarrhea Despite SSA Therapy
  • Advanced & Metastatic Carcinoid Syndrome
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.7% of the carcinoid syndrome diarrhea treatment market share in 2025. The region benefits from dense U.S. referral networks, established telotristat ethyl reimbursement, and a regulatory setting that has supported orphan drug and breakthrough therapy programs. Teva’s October 2024 generic octreotide launch introduced pricing pressure in an SSA segment that had been brand-exclusive for a long period. Branded volumes retain some support from buy-and-bill practices, cold-chain requirements, and established prescribing patterns. Canada and Mexico add regional volume through SSA prescribing, while Canadian academic programs are extending PRRT access.

Europe is the second-largest regional contributor to the carcinoid syndrome diarrhea treatment market. Germany, the UK, France, Italy, and Spain form the core of SSA and PRRT activity. ENETS-certified centers and European guidelines support the structured sequencing of SSA therapy, telotristat ethyl, and PRRT. The 2026 GGNET Delphi consensus recommended structured PRRT selection and multidisciplinary tumor board review for SSTR-positive NETs. Italy’s 26.5% interregional mobility rate for radioligand therapy hospitalizations indicates the importance of additional nuclear medicine capacity. Argentina and Colombia have also formalized first-line SSA treatment in recent clinical guidance.

Asia-Pacific is forecast to grow at a 9.5% CAGR through 2031, the fastest regional rate in the carcinoid syndrome diarrhea treatment market. China published its first dedicated carcinoid syndrome diagnosis and treatment consensus in 2025, endorsing SSAs as first-line therapy and telotristat ethyl for SSA-refractory diarrhea. Japan’s universal health insurance system covers approved NET therapies as PRRT capacity expands. Australia added PRRT with 177Lu-DOTATATE to the Medicare Benefits Schedule from November 1, 2025. The change reduces patient costs and supports additional PRRT center development. India, South Korea, other APAC markets, the Middle East, and Africa remain early-stage contributors where awareness and infrastructure investment matter more than new therapy launches.

List of Companies Covered in this Report:

• Ipsen
• Novartis
• Lexicon Pharmaceuticals, Inc.
• Pfizer
• Teva Pharmaceutical Industries
• Sun Pharmaceuticals Industries
• AstraZeneca
• Bristol-Myers Squibb
• Cipla
• Recordati S.p.A.
• TerSera Therapeutics LLC
• ITM Isotope Technologies Munich SE
• Sirtex Medical Limited
• Boston Scientific
• Merck
• Takeda Pharmaceuticals
• Crinetics Pharmaceuticals, Inc.
• Chiasma, Inc.
• Wockhardt Limited
• Pharmascience

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support